Editas Medicine, Inc. 8-K

What Happened
Editas Medicine, Inc. filed a Form 8-K on April 7, 2026, disclosing that on April 1, 2026 its Audit Committee dismissed Ernst & Young LLP as the company's independent registered public accounting firm and appointed PricewaterhouseCoopers LLP (PwC) to serve as the new independent auditor for the fiscal year ending December 31, 2026. The Audit Committee said the decision followed soliciting proposals from other firms and a formal review; the company notified Ernst & Young on April 2, 2026.

Key Details

• Dismissal effective April 1, 2026; PwC appointed to audit fiscal year ending December 31, 2026.
• Ernst & Young’s audit reports for the years ended Dec 31, 2024 and Dec 31, 2025 were unmodified (no adverse opinions or disclaimers).
• The company reported no “disagreements” or “reportable events” with Ernst & Young for fiscal years 2024 and 2025 and through April 1, 2026.
• The Form 8-K is dated April 7, 2026 and was signed by Chief Financial Officer Amy Parison; the filing includes a letter from Ernst & Young to the SEC (Exhibit 16.1).

Why It Matters
An auditor change is a material governance event investors watch because the independent auditor will examine and sign off on future financial statements. In this case, the filing notes no audit disagreements or reportable events and prior-year reports were unmodified, which suggests the change was not the result of a disclosed dispute. Investors should note PwC will audit Editas’s 2026 financials and monitor upcoming quarterly and annual filings for any additional disclosure about the transition or audit timing.